CERUS CORP
Cerus is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System, which is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its platelet and plasma systems are marketed and sold in the U.S. and other countries. The company also sells the INTERCEPT Blood System for Cryoprecipitation, used to produce INTERCEPT Fibrinogen Complex for treatment and control of bleeding associated with fibrinogen deficiency, and pathogen-reduced plasma. The red blood cell system remains in development. Cerus also commercializes an LED-based INTERCEPT Illuminator in a number of countries in Europe and selected other regions. Cerus sells its platelet and plasma systems through a direct sales force and distributors. In the U.S., it sells INTERCEPT Fibrinogen Complex or disposable kits used to manufacture it through its direct sales force. Its products use disposable kits, inactivation compounds and illuminators. Cerus is headquartered in Concord, California.
No SEC Form 4 filings for $CERS in the last 30 days.
See all $CERS insider activity →Cerus Corporation reported Q3 GAAP EPS of $0.00, beating estimates by $0.01, with revenue of $64M, a 6.3% year-over-year increase and $2.9M above expectations. The company reiterated its full-year 2026 product revenue guidance.
CERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerus Corporation Announces Third Quarter 2026 Financial Results Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red bl
Cerus Corporation reported that its INTERCEPT Red Blood Cells (RBCs) met the primary efficacy endpoint in a Phase 3 trial, showing non-inferiority to conventional RBCs in adjusted hemoglobin increment. The study also met primary safety endpoints, with no significant differences in treatment-emergent adverse events between the treatment and control arms. Cerus plans to submit full study results for peer-reviewed publication and presentation at scientific meetings.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning CERS (CERUS CORP). Coverage has skewed bullish: 3 bullish, 3 neutral, and 1 bearish.
Recent CERS coverage spans earnings, financial news and corporate actions.
Beat on both EPS and revenue, with guidance reiterated, should support near-term sentiment and reduce downside risk versus prior expectations.
Cerus posted solid quarter and maintained guidance, suggesting continued growth momentum.
Cerus Corporation reported that its INTERCEPT Red Blood Cells (RBCs) met the primary efficacy endpoint in a Phase 3 trial, showing non-inferiority to conventional RBCs in adjusted hemoglobin increment. The study also met primary safety endpoints, with no significant differences in treatment-emergent adverse events between the treatment and control arms. Cerus plans to submit full study results for peer-reviewed publication and presentation at scientific meetings.
Ahead of the Nov 2 after-hours earnings release, traders can position around the upcoming print versus the provided EPS and revenue expectations.
This is a disclosed ownership change below the 5% threshold, with limited direct fundamentals impact but potential sentiment/positioning signal.
AlphAI scores every news story that mentions CERS with an AI model for sentiment and relevance, and aggregates insider trades from CERUS CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cerus Corporation reported Q3 GAAP EPS of $0.00, beating estimates by $0.01, with revenue of $64M, a 6.3% year-over-year increase and $2.9M above expectations. The company reiterated its full-year 2026 product revenue guidance.
2 min readCERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerus Corporation Announces Third Quarter 2026 Financial Results Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red bl
2 min readCerus Corporation reported that its INTERCEPT Red Blood Cells (RBCs) met the primary efficacy endpoint in a Phase 3 trial, showing non-inferiority to conventional RBCs in adjusted hemoglobin increment. The study also met primary safety endpoints, with no significant differences in treatment-emergent adverse events between the treatment and control arms. Cerus plans to submit full study results for peer-reviewed publication and presentation at scientific meetings.
2 min readCerus Corporation (CERS) is expected to report Q3'26 earnings on November 02. Analysts project revenue of $63.25 million and an EPS of -$0.01. Results will be announced after market close.
1 min readBaker Bros. Advisors LP and related reporting persons filed Amendment No. 13 to a Schedule 13G showing beneficial ownership of 6,395,431 Cerus Corp (CERS) shares, or 3.2% of 201,457,000 shares outstanding as of June 30, 2026. Julian C. Baker and Felix J. Baker each report 19,864 shares individually, each totaling about 3.2%.
2 min readCERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerus Corporation Announces Second Quarter 2026 Financial Results Second Quarter 2026 Total Revenue of $63.3 million; Second Quarter 2026 Product Revenue of $57.4 million, +10% Y/Y Raising Lower End of 2026 Product Revenue Guidance: Range now $229 to $231 million; Ra
6 min readCERUS CORP (CERS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001020214 0001020214 2026-07-06 2026-07-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2
2 min readCERUS CORP (CERS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001020214 0001020214 2026-06-05 2026-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05,
4 min readJayaraman Vivek K (Chief Operating Officer) sold 16,667 shares of CERUS CORP (CERS) at $3.00 on 2026-05-29 under a Rule 10b5-1 trading plan.
1 min readCerus Corporation reported strong financial results for the first quarter of 2026, with total revenue increasing by 23% to $59.9 million and product revenue by 24% to $53.7 million. The company significantly narrowed its net loss to $1.6 million and saw increased demand for its INTERCEPT Fibrinogen Complex. Based on this performance, Cerus raised its full-year 2026 product revenue guidance to a range of $227 million to $231 million.
2 min read
